Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genetic Ablation of CD33 in Hematopoietic Stem Cells to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with Acute Myeloid Leukemia (AML)

NCT05662904 is registered in ClinicalTrials.gov with German Cancer Research Center as lead sponsor.

NCT NCT05662904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05662904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genetic Ablation of CD33 in Hematopoietic Stem Cells to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with Acute Myeloid Leukemia (AML)
Lead sponsor
German Cancer Research Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2028
Completion date
January 31, 2030
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia (aml)